Navigation Links
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
Date:3/8/2011

EAST HANOVER, N.J., March 8, 2011 /PRNewswire/ -- An advisory committee recommended today that the Food and Drug Administration (FDA) approve QAB149 (indacaterol) 75 mcg in the US as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

The committee voted 13 to four in favor of recommending approval of the 75 mcg dose. The advisory committee also voted 12 to five against recommending approval of the 150 mcg dose. The 75 mcg dose was seen as effective as the 150 mcg dose and the committee endorsed the safety of both doses.

The recommendation by the Pulmonary-Allergy Drug Advisory Committee (PADAC) followed a request from the FDA to further explore the efficacy and safety of lower doses of QAB149, an investigational medicine in the long-acting beta2-agonist (LABA) class.

The FDA has the option of seeking the advice of its advisory committees when it is reviewing a new drug for approval, although it is not obliged to follow the committee's recommendations.

"Novartis is committed to addressing the needs of patients with COPD and we are encouraged by the advisory committee's recommendation for approval of QAB149," said Trevor Mundel, MD, Global Head of Development at Novartis Pharma AG. "The company is focused on bringing innovative, safe and effective treatment options to patients and physicians, and we will work closely with the FDA as it completes its review of QAB149."

The advisory committee reviewed an extensive program of clinical trials in which the efficacy of QAB149 at 75 and 150 mcg was studied in a total of 1,282 COPD patients in five key Phase III trials lasting 12-26 weeks. Results showed that both doses of QAB149 significantly improved lung function compared to placebo. These improvements were seen five minutes after the first dose and lasted for 24 hours.

The clinical tri
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Myriant Technologies, Inc. Announces J. Brian Ferguson to Join Advisory Board
2. Sensus Healthcare Announces the Formation of a Medical Advisory Board
3. Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India
4. Leading Dental Stem Cell and Regenerative Medicine Researcher Dr. George Huang Joins StemSaves Science Advisory Council
5. Carl A. Miller, PhD, Joins iDiverses Business and Scientific Advisory Board
6. Dr. Russell L. Chapman Joins Aquatic Energy as the Chairman of its Science Advisory Board
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. IGEN Networks Corp continues to build a world class advisory board, with the appointment of three new members
9. IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD
10. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
11. Signal Genetics Announces Establishment of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... May 11 /PRNewswire-Asia-FirstCall/ -- China,Baicaotang Medicine Ltd. (OTC Bulletin Board: ... in the, Guangxi Province of China announced today that ... the,Company. , , , ... Mr. Tang Hui Tian , Chairman and CEO of CBT, ...
... China , May 11 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... on researching, developing, manufacturing and marketing,biopharmaceutical products, today announced that it will ... on May 16, 2010 ,at 8:00pm (Eastern). , ... Following ...
... GARDENA, Calif. , May 11 Trans World Alloys ... proudly announces the grand opening of their state-of-the-art, 40,000 square foot service center ... , , ... , , ...
Cached Biology Technology:Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 2Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 33SBio Inc. To Report 2010 First Quarter Unaudited Financial Results on May 16, 2010 2Titanium and Aluminum Distributor, Trans World Alloys Relocates to Its Newly Built, State-of-the-Art Headquarters in Gardena, California 2
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
(Date:7/23/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) has ... of the Biometrics Industry 2015 " report ... biometrics market is likely to witness significant growth ... the uptake of multiple technologies available. The year ... growth of biometrics in existing applications as well ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... The presence of drug-resistant, pathogenic bacteria on uncooked poultry ... to antibiotic use in production, according to researchers at ... study is the first to directly compare bacterial contamination ... producers who use antibiotics and from those who claim ...
... first comprehensive survey of gene activity in the X ... variation among individuals, according to new work by researchers ... Policy (IGSP) and Pennsylvania State University. , The results ... traits among women and between males and females, in ...
... the University of Maryland have identified a cricket living ... Finicky mating behavior appears to be the driving force ... scientists wrote in the Jan. 27 issue of Nature ... differences in the pulse rates of male courtship songs, ...
Cached Biology News:Drug-resistant bacteria on poultry products differ by brand 2Drug-resistant bacteria on poultry products differ by brand 3Variation in women's X chromosomes may explain differences among individuals, between sexes 2Variation in women's X chromosomes may explain differences among individuals, between sexes 3Cricket's finicky mating behavior boosts biodiversity 2Cricket's finicky mating behavior boosts biodiversity 3
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
... is designed to allow neomycin/kanamycin selection ... The loxP-PGK-gb2-neo-loxP template encodes the neomycin/kanamycin ... promoter (gb2) for expression of kanamycin ... promoter (PGK) for expression of neomycin ...
... These precision 5mm diameter, 7 inch long PYREX ... for compatibility with ground joints, valves, and vacuum ... spectrometers running from 300 to 500MHz. They have ... I.D. of 4.20 + 0.013-0.000mm. These NMR tubes ...
Biology Products: